UnknownNot Applicable

Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine

Italy200 participantsStarted 2016-01

Plain-language summary

observational prospective study, designed for patients with colorectal cancer receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed written informed consent * Age ≥ 18 years * Histologically confirmed adenocarcinoma of colon or rectum (any T, any N, any M) receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations Exclusion Criteria: * Prior treatment with fluoropyrimidines * Prior or concurrent chest radiotherapy * Any prior or concurrent treatment with cardiotoxic drug * Any serious or uncontrolled cardiovascular disease (defined by the specialist during cardiac examination, see section 6.3.2 for details )

What they're measuring

Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU

Timeframe: 24 months

Trial details

NCT IDNCT02665312

SponsorFondazione del Piemonte per l'Oncologia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-01

Contact for this trial

Celeste Cagnazzo, PhD

00390119933851 celeste.cagnazzo@ircc.it

View on ClinicalTrials.gov More Colorectal Cancer trials